MedPath

Sumaxin

sumaxin (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads

Approved
Approval ID

5d9ddc1a-fbae-4595-86ce-3bbca7d03482

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 15, 2023

Manufacturers
FDA

Medimetriks Pharmaceuticals, Inc.

DUNS: 019903816

Products 2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

sulfacetamide sodium and sulfur

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code43538-101
Product Classification
G
Generic Name
sulfacetamide sodium and sulfur
Product Specifications
Effective DateDecember 15, 2023
FDA Product Classification

sulfacetamide sodium and Sulfur

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code43538-100
Product Classification
G
Generic Name
sulfacetamide sodium and Sulfur
Product Specifications
Route of AdministrationTOPICAL
Effective DateDecember 15, 2023
FDA Product Classification

INGREDIENTS (16)

Sulfacetamide sodiumActive
Quantity: 100 mg in 1 g
Code: 4NRT660KJQ
Classification: ACTIB
aloeInactive
Code: V5VD430YW9
Classification: IACT
SulfurActive
Quantity: 40 mg in 1 g
Code: 70FD1KFU70
Classification: ACTIB
cetyl alcoholInactive
Code: 936JST6JCN
Classification: IACT
butylated hydroxytolueneInactive
Code: 1P9D0Z171K
Classification: IACT
edetate disodiumInactive
Code: 7FLD91C86K
Classification: IACT
glycerinInactive
Code: PDC6A3C0OX
Classification: IACT
green tea leafInactive
Code: W2ZU1RY8B0
Classification: IACT
methylparabenInactive
Code: A2I8C7HI9T
Classification: IACT
propylparabenInactive
Code: Z8IX2SC1OH
Classification: IACT
waterInactive
Code: 059QF0KO0R
Classification: IACT
sodium lauryl sulfoacetateInactive
Code: D0Y70F2B9J
Classification: IACT
sodium thiosulfateInactive
Code: HX1032V43M
Classification: IACT
stearyl alcoholInactive
Code: 2KR89I4H1Y
Classification: IACT
sodium cocoyl isethionateInactive
Code: 518XTE8493
Classification: IACT
disodium oleamido monoethanolamine sulfosuccinateInactive
Code: 5M1101WGSY
Classification: IACT

Drug Labeling Information

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

LOINC: 51945-4Updated: 12/15/2023

PRINCIPAL DISPLAY PANEL - Kit Carton

NDC 43538-101-60

Rx Only
sumaxin**®**
(Sodium Sulfacetamide 10%
& Sulfur 4%) Cleansing Pads
CP
KIT

CONTENTS:

1 -

Sumaxin® (Sodium Sulfacemide 10% & Sulfur 4%)  

Cleansing Pads Carton - 60 Pads (Net wt. 3.7 g each)

1 -

Rehyla® Wash Moisturizing Daily Wash (16 fl. oz.)

MEDIMETRIKS
PHARMACEUTICALS, INC.

PRINCIPAL DISPLAY PANEL - Kit Carton

INDICATIONS & USAGE SECTION

LOINC: 34067-9Updated: 12/15/2023

INDICATIONS

Sumaxin**®**** (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads**are indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.

CONTRAINDICATIONS SECTION

LOINC: 34070-3Updated: 12/15/2023

CONTRAINDICATIONS

Sumaxin**®**** (sodium sulfacetamide 10% & sulfur 4%) Cleansing Padsare contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. Sumaxin****®**** (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads**are not to be used by patients with kidney disease.

ADVERSE REACTIONS SECTION

LOINC: 34084-4Updated: 12/15/2023

ADVERSE REACTIONS

Although rare, sodium sulfacetamide may cause local irritation.

SPL UNCLASSIFIED SECTION

LOINC: 42229-5Updated: 12/15/2023

To reportSUSPECTED ADVERSE REACTIONS, contact Medimetriks Pharmaceuticals, Inc., at 1-973-882-7512 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Manufactured for:
MEDIMETRIKS
PHARMACEUTICALS, INC.

383 Route 46 West
Fairfield, NJ 07004-2402 USA

www.medimetriks.com

IP001-R5
Rev. 10/17

CLINICAL PHARMACOLOGY SECTION

LOINC: 34090-1Updated: 12/15/2023

CLINICAL PHARMACOLOGY

The most widely accepted mechanism of action of sulfonamides is the Woods- Fildes theory, which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid (PABA), an essential component for bacterial growth. While absorption through intact skin has not been determined, sodium sulfacetamide is readily absorbed from the gastrointestinal tract when taken orally and excreted in the urine, largely unchanged. The biological half-life has variously been reported as 7 to 12.8 hours. The exact mode of action of sulfur in the treatment of acne is unknown, but it has been reported that it inhibits the growth of Propionibacterium acnes and the formation of free fatty acids.

WARNINGS SECTION

LOINC: 34071-1Updated: 12/15/2023

WARNINGS

Although rare, sensitivity to sodium sulfacetamide may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice, and contact dermatitis indicate hypersensitivity to sulfonamides. Particular caution should be employed if areas of denuded or abraded skin are involved.

**FOR EXTERNAL USE ONLY.**Keep away from eyes. Keep out of reach of children. Keep container tightly closed.

DOSAGE & ADMINISTRATION SECTION

LOINC: 34068-7Updated: 12/15/2023

DOSAGE AND ADMINISTRATION

Wash affected area(s) with cleansing pad once or twice daily, or as directed by your physician. Wet area(s) with water. Wet pad with a little water and work into a full lather. Cleanse area(s) with pad for 10-20 seconds, avoiding eyes. Rinse thoroughly and pat dry. Discard pad. Do not flush.

DESCRIPTION SECTION

LOINC: 34089-3Updated: 12/15/2023

DESCRIPTION

Sodium sulfacetamide is a sulfonamide with antibacterial activity while sulfur acts as a keratolytic agent. Chemically sodium sulfacetamide is N-[(4-aminophenyl) sulfonyl]-acetamide, monosodium salt, monohydrate. The structural formula is:

Chemical Structure

Each pad of** Sumaxin****®**** (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads**is coated with a cleanser-based formulation. Each gram of this cleanser-based formulation contains 100 mg of Sodium Sulfacetamide and 40 mg of Sulfur. The cleanser base consists of: aloe, butylated hydroxytoluene, cetyl alcohol, disodium oleamido MEA sulfosuccinate, edetate disodium, fragrance, glycerin, glyceryl stearate/PEG-100 stearate, green tea, methylparaben, propylparaben, purified water, sodium cocoyl isethionate, sodium lauryl sulfoacetate, sodium thiosulfate, stearyl alcohol.

PRECAUTIONS SECTION

LOINC: 42232-9Updated: 12/15/2023

PRECAUTIONS

General

If irritation develops, use of the product should be discontinued and appropriate therapy instituted. Patients should be carefully observed for possible local irritation or sensitization during long-term therapy. The object of this therapy is to achieve desquamation without irritation, but sodium sulfacetamide and sulfur can cause reddening and scaling of the epidermis. These side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility.

Information for Patients

Avoid contact with eyes, eyelids, lips and mucous membranes. If accidental contact occurs, rinse with water. If excessive irritation develops, discontinue use and consult your physician.

Carcinogenesis, Mutagenesis and Impairment of Fertility

Long-term studies in animals have not been performed to evaluate carcinogenic potential.

PREGNANCY

Category C

Animal reproduction studies have not been conducted with** Sumaxin****®**** (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads**. It is also not known whether** Sumaxin****®**** (sodium sulfacetamide 10% & sulfur 4%) Cleansing Padscan cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sumaxin****®**** (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads**should be given to a pregnant woman only if clearly needed.

NURSING MOTHERS

It is not known whether sodium sulfacetamide is excreted in the human milk following topical use of** Sumaxin****®**** (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads**. However, small amounts of orally administered sulfonamides have been reported to be eliminated in human milk. In view of this and because many drugs are excreted in human milk, caution should be exercised when** Sumaxin****®**** (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads**are administered to a nursing woman.

PEDIATRIC USE

Safety and effectiveness in children under the age of 12 have not been established.

HOW SUPPLIED SECTION

LOINC: 34069-5Updated: 12/15/2023

HOW SUPPLIED

Sumaxin**®**** (sodium sulfacetamide 10% & sulfur 4%) Cleansing Pads**are available in boxes of 60 cloths (3.7 g), NDC 43538-100-60.

Store at 15°-30° C (59°-86° F).

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Sumaxin - FDA Drug Approval Details